RBC Capital lowered the firm’s price target on Adverum Biotechnologies (ADVM) to $4 from $5 and keeps a Sector Perform rating on the shares after its Q1 results. The company’s first US-based wet AMD pivotal study is underway and is enrolling both treatment-experienced and treatment-naive patients, though the firm’s reduced price target reflects Adverum’s financial overhang as it remains on the sidelines pending further de-risking, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADVM:
- Adverum Biotechnologies reports Q1 EPS ($2.25), consensus ($1.97)
- Adverum Biotechnologies: Promising Gene Therapy Developments and Financial Stability Justify Buy Rating
- Adverum Biotechnologies Reports 2024 Financial Results and Pipeline Progress
- Adverum Biotechnologies reports Q4 EPS ($1.96), consensus ($1.38)
- Adverum Biotechnologies sees cash runway into 2H25